
Ä¡¸Å±³°ú¼ (Ä¡¸Å-ÀÓ»óÀû Á¢±Ù)
- ÀúÀÚ(±Û)´ëÇÑÄ¡¸ÅÇÐȸ
- ÃâÆÇ»ç´ëÇÑÀÇÇмÀû
- ¹ßÇàÀÏ2006³â 4¿ù
Ä¡¸Å¿Í ¼ö¸éÀÇ °ü·Ã¼º ¿¬±¸ÇØ Çа迡 ¼Ò°³
ÁÖ¿ä Áø·á ºÐ¾ßÀÎ Ä¡¸Å, ±â¾ïÀå¾Ö, °æµµÀÎÁö±â´ÉÀå¾Ö, ³úÁ¹Áß°ú °ü·ÃÇØ ±¹³»¿¡¼ ¼Õ²ÅÈ÷´Â ÀÇ»ç´Ù. ±× Áß Ä¡¸ÅȯÀÚ¿¡°Ô Àß ³ªÅ¸³ª´Â ¼ö¸é ¹®Á¦¿¡ °ü½ÉÀÌ ¸¹¾Æ Ä¡¸Å¿Í ¼ö¸éÀÇ °ü·Ã¼ºÀ» ¿¬±¸ÇØ Çа迡 ¼Ò°³ÇßÀ¸¸ç, Ä¡¸ÅȯÀÚ º¸È£ÀÚ¿¡°Ô ³ªÅ¸³ª´Â ¼ö¸éÀå¾Ö¿Í ¼ö¸éÀÇ Áú¿¡ ´ëÇÑ ¿¬±¸¸¦ ÁøÇàÇϱ⵵ Çß´Ù. ¶ÇÇÑ ¡®Ä¡¸Å ÀÓ»óÀû Á¢±Ù¡¯À̶ó´Â ±³°ú¼µµ ÁýÇÊÇß´Ù.
Á¦ ¸ñ | Association between APOE ¥å2 and A¥â burden in patients with Alzheimer- and vascular-type cognitive impairment | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2020.1 | ¹ßÇ¥Áö |
Á¦ ¸ñ | Interactive Effects of Apolipoprotein E epsilon 4 and Triiodothyronine on Memory Performance in Patients With Subjective Cognitive Decline | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2020.06 | ¹ßÇ¥Áö |
Á¦ ¸ñ | Differences in neuroimaging features of early-versus late-onset nonfluent/agrammatic primary progressive aphasia | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2020.02 | ¹ßÇ¥Áö |
Á¦ ¸ñ | A Comparison Study of Cilostazol and Aspirin on Changes in Volume of Cerebral Small Vessel Disease White Matter Changes: Protocol of a Multicenter, Randomized Controlled Trial | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2019.12 | ¹ßÇ¥Áö |
Á¦ ¸ñ | Cognition enhancing effect of panax ginseng in Korean volunteers with mild cognitive impairment: a randomized, double-blind, placebo-controlled clinical trial | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2019.09 | ¹ßÇ¥Áö |
Á¦ ¸ñ | ´ÜÀÏ ±â°ü¿¡¼ °æÇèÇÑ ºñ±â¾ï»ó½ÇÇü °æµµ ÀÎÁöÀå¾ÖÀÇ ÀÓ»óÀû °íÂû | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2019.08 | ¹ßÇ¥Áö |
Á¦ ¸ñ | Distinct Brain Regions in Physiological and Pathological Brain Aging | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2019.06 | ¹ßÇ¥Áö |
°æÈñ´ëÇб³º´¿øÀº ȯÀÚ Áß½ÉÀÇ ÀÇ·á ¼ºñ½º¸¦ Á¦°øÇϸç, ±¹³» ÀÇ·á°è¸¦ ¼±µµÇÏ´Â »ó±ÞÁ¾ÇÕº´¿øÀÔ´Ï´Ù. ÃֽŠÀÇ·á ±â¼ú°ú Àåºñ¸¦ Ȱ¿ëÇÏ¿© ȯÀڵ鿡°Ô ÃÖ»óÀÇ Ä¡·á¸¦ Á¦°øÇÕ´Ï´Ù. ƯÈ÷ ÁßÁõÁúȯ Ä¡·á ¹× ¿¬±¸¿¡ °Á¡À» º¸À̸ç, ´ÙÇÐÁ¦ ÇùÁø ½Ã½ºÅÛÀ» ÅëÇØ ȯÀÚÀÇ °Ç°À» ÃÖ¿ì¼±À¸·Î »ý°¢ÇÕ´Ï´Ù. °æÈñ´ëÇб³º´¿øÀº ȯÀÚµéÀÇ ½Å·Ú¿Í ¸¸Á·µµ¸¦ ³ôÀÌ´Â µ¥ ÁÖ·ÂÇϸç, Áö¼ÓÀûÀ¸·Î ÀÇ·á ǰÁú Çâ»ó°ú ¿¬±¸ °³¹ß¿¡ Èû¾²°í ÀÖ½À´Ï´Ù.
¼¿ïƯº°½Ã µ¿´ë¹®±¸ °æÈñ´ë·Î 23 °æÈñ´ëÇб³º´¿ø